ConductScience.org, home

Paper · 36498669

References145

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118355325Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.Diabetes Obes Metab2008https://conductscience.org/library/papers/18355325PubMed
224622369Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Diabetes Endocrinol2013https://conductscience.org/library/papers/24622369PubMed
315549021Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002.MMWR Morb Mortal Wkly Rep2004https://conductscience.org/library/papers/15549021PubMed
417223217Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.Diabetes Res Clin Pract2007https://conductscience.org/library/papers/17223217PubMed
518355324Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.Diabetes Obes Metab2008https://conductscience.org/library/papers/18355324PubMed
627171508Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.J Diabetes2017https://conductscience.org/library/papers/27171508PubMed
723279307Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.Diabetes Obes Metab2013https://conductscience.org/library/papers/23279307PubMed
820332588Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.Endocr J2010https://conductscience.org/library/papers/20332588PubMed
916189256Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.J Clin Endocrinol Metab2005https://conductscience.org/library/papers/16189256PubMed
1021146883Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients.Diabetes Res Clin Pract2011https://conductscience.org/library/papers/21146883PubMed
1124400655Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.Diabetes Obes Metab2014https://conductscience.org/library/papers/24400655PubMed
1227088241Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.Ann Intern Med2016https://conductscience.org/library/papers/27088241PubMed
1318201212Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.Diabet Med2008https://conductscience.org/library/papers/18201212PubMed
1416823726Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.Horm Metab Res2006https://conductscience.org/library/papers/16823726PubMed
1525238025Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.Diabetes Obes Metab2015https://conductscience.org/library/papers/25238025PubMed
1620334663Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study.Cardiovasc Diabetol2010https://conductscience.org/library/papers/20334663PubMed
1715154941An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.Diabet Med2004https://conductscience.org/library/papers/15154941PubMed
1812682825Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients.Acta Diabetol2003https://conductscience.org/library/papers/12682825PubMed
1919622552The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.BMJ2009https://conductscience.org/library/papers/19622552PubMed
2018495285Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.Diabetes Res Clin Pract2008https://conductscience.org/library/papers/18495285PubMed

papers-2026-11-12-0.1.0

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/36498669/references